Amgen and AstraZeneca announced that TEZSPIRE (tezepelumab-ekko) achieved statistically significant and clinically meaningful results across both co-primary endpoints and all key secondary endpoints in the Phase 3 CROSSING trial in eosinophilic esophagitis, with benefits sustained through week 52.
Merck and Moderna announced that the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its RFS and DMFS endpoints in resected stage IIB-IV melanoma, the first positive Phase 3 result for an individualized neoantigen therapy.
AstraZeneca has officially stopped its Phase III eVOLVE-Lung02 trial evaluating volrustomig plus chemotherapy in first-line metastatic NSCLC following a recommendation from the Independent Data Monitoring Committee.
The European Medicines Agency has validated Pfizer and Valneva’s Marketing Authorization Application for PF-07307405, a 6-valent Lyme disease vaccine candidate that showed over 70% efficacy in the Phase 3 VALOR trial.
Novo Nordisk has released headline results from the Phase 3 ZEUS cardiovascular outcomes trial evaluating monthly subcutaneous ziltivekimab in patients with ASCVD, CKD, and elevated systemic inflammation.
Sanofi has discontinued amlitelimab in moderate-to-severe atopic dermatitis and will not pursue global regulatory submissions, citing ESTUARY phase 3 data that did not show a meaningful edge over standard of care. Full-year 2026 guidance is unaffected.
Roche’s next-generation KRAS G12C inhibitor, divarasib, has achieved statistical significance in a global head-to-head Phase III trial against sotorasib and adagrasib for advanced non-small cell lung cancer.
BridgeBio Pharma and Kyowa Kirin announced the publication of positive data from the global Phase 3 PROPEL 3 study of oral infigratinib for pediatric achondroplasia in The New England Journal of Medicine (NEJM), demonstrating unparalleled improvements in annualized height velocity and body proportionality.
Pfizer has announced topline Phase 3 results from its SigVie-002 study evaluating the investigational antibody-drug conjugate sigvotatug vedotin in previously treated metastatic non-squamous non-small cell lung cancer.
Kura Oncology and Kyowa Kirin announced updated frontline data for ziftomenib combined with 7+3 chemotherapy in newly diagnosed NPM1-m and KMT2A-r AML patients, demonstrating high complete response rates and deep MRD negativity ahead of the EHA 2026 Congress.
